Pubblicazioni

Ferritin-based disruptor nanoparticles: A novel strategy to enhance LDL cholesterol clearance via multivalent inhibition of PCSK9–LDL receptor interaction

2024 - PROTEIN SCIENCE
Incocciati, A.; Cappelletti, C.; Masciarelli, S.; Liccardo, F.; Piacentini, R.; Giorgi, A.; Bertuccini, L.; De Berardis, B.; Fazi, F.; Boffi, A.; Bonamore, A.; Macone, A.

Efficacy and safety of PCSK9 monoclonal antibodies

2019 - EXPERT OPINION ON DRUG SAFETY
Iqbal, Z.; Dhage, S.; Mohamad, J. B.; Abdel-Razik, A.; Donn, R.; Malik, R.; Ho, J. H.; Liu, Y.; Adam, S.; Isa, B.; Stefanutti, C.; Soran, H.

Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): the promises of PCSK9 inhibitors

2017 - ATHEROSCLEROSIS
Arca, M

A review of PCSK9 inhibition and its effects beyond LDL receptors

2016 - JOURNAL OF CLINICAL LIPIDOLOGY
Dixon, Dave L.; Trankle, Cory; Buckley, Leo; Parod, Eric; Carbone, Salvatore; Van Tassell, Benjamin W.; Abbate, Antonio

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma